A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
1 juin 2018 mis à jour par: AbbVie (prior sponsor, Abbott)
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose.
(This portion of the study is complete).
The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy.
Aperçu de l'étude
Statut
Complété
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
86
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Edmonton, Canada, T6G 1Z2
- Site Reference ID/Investigator# 7493
-
Ottawa, Canada, K1H 8L6
- Site Reference ID/Investigator# 7635
-
-
-
-
-
Leicester, Royaume-Uni, LE1 5WW
- Site Reference ID/Investigator# 18541
-
Manchester, Royaume-Uni, M20 4BX
- Site Reference ID/Investigator# 2622
-
-
-
-
Arizona
-
Peoria, Arizona, États-Unis, 85381
- Site Reference ID/Investigator# 13605
-
Phoenix, Arizona, États-Unis, 85013
- Site Reference ID/Investigator# 5261
-
-
California
-
Los Angeles, California, États-Unis, 90095-7187
- Site Reference ID/Investigator# 11942
-
Sacramento, California, États-Unis, 95817
- Site Reference ID/Investigator# 4718
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045-0510
- Site Reference ID/Investigator# 3755
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Site Reference ID/Investigator# 8324
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Site Reference ID/Investigator# 2623
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21231-1000
- Site Reference ID/Investigator# 2625
-
Bethesda, Maryland, États-Unis, 20892
- Site Reference ID/Investigator# 12343
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Site Reference ID/Investigator# 11941
-
Boston, Massachusetts, États-Unis, 02215
- Site Reference ID/Investigator# 2626
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Site Reference ID/Investigator# 4934
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Site Reference ID/Investigator# 2624
-
-
Washington
-
Tacoma, Washington, États-Unis, 98405
- Site Reference ID/Investigator# 6650
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- The subject must be >=18 years of age.(Phase 1 & 2a)
- Histologically and/or cytologically documented diagnosis of small cell lung cancer (North America & UK) or other non-hematological malignancy (North America only).(Phase 1 only)
- Histologically and/or cytologically documented diagnosis of SCLC.(Phase 2a)
- At least one prior chemotherapy treatment regimen(s) and their disease is refractory or experienced progressive disease following the treatment.(Phase 1)
- Extensive-stage SCLC & is chemotherapy naïve(US only) has experienced progressive disease following at least one chemotherapy regimen or their disease is refractory.(Phase 2a)
- Brain metastases with clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function & no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the first dose of study drug.
- ECOG performance score <= 2(Ph 1) <=1(Phase 2a)
- Must be receiving a stable dose of Selective Serotonin Reuptake Inhibitor (SSRI) anti-depressants 21 days prior to 1st dose of study drug.
Adequate bone marrow, renal & hepatic function per local lab reference range at Screening as follows:
- Bone marrow: Absolute Neutrophil count (ANC)>=1000/µL
- Platelets>= 100,000/mm3
- Hemoglobin>=9.0g/dL
- Renal function: Serum creatinine<= 2.0mg/dL or calculated creatinine clearance>=50mL/min
- Hepatic function&enzymes: AST and ALT<=3.0 x the upper normal limit(ULN) of institution's normal range
- Bilirubin<=1.5xULN. If Gilbert's Syndrome may have Bilirubin> 1.5 x ULN
- Coagulation: aPTT and PT<=1.2 x the upper limit of normal
- Should have archived diagnostic tissue available for assessment of Bcl-2 family protein expression.(Phase 2a)
- All female subjects not surgically sterile or postmenopausal(for at least 1 year)and non-vasectomized male subject must practice at least one method of birth control.
Exclusion Criteria:
- Underlying or predisposing condition of bleeding or currently exhibits signs of bleeding.
- Recent history of non-chemotherapy induced thrombocytopenia associated bleeding within 1 year prior to first dose of study drug.
- Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.
- The subject has active immune thrombocytopenic purpura (ITP),active autoimmune hemolytic anemia (AIHA), or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug).
- Currently receiving or requires anticoagulation therapy or any drug or herbal supplements that affect platelet function, with exception of low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter.
- Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for hypothyroidism or estrogen replacement therapy (ERT), anti estrogen analogs, agonists required to suppress serum testosterone levels), or any investigational therapy within 14 days prior to the first dose of study drug, or has not recovered to less than a grade 2 adverse effect(s) of the previous therapy.
- Received a biologic (G-CSF, GM-CSF or erythropoietin) within 28 days prior to the first dose of study drug.
- Steroid therapy for anti-neoplastic intent within seven days prior to the first dose of study drug.
- Has consumed grapefruit or grapefruit products within 3 days prior to the first dose of study drug.
- Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.
- Positive for HIV
A history of other active malignancies within the past 3 years prior to screening, with the exception of:
- Adequately treated in situ carcinoma of the cervix uteri
- Basal or squamous cell carcinoma of the skin
- Previous malignancy confined and surgically resected with curative intent
Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
- Active systemic fungal infection
- Diagnosis of fever and neutropenia within 1 week prior to study drug administration.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Phase 1 and Phase 2a
|
Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing. - 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study. Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing. - 40 patients with SCLC |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Safety assessment
Délai: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
|
Dose limiting toxicity determination
Délai: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
|
Maximum tolerated dose determination
Délai: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
|
Pharmacokinetic profile evaluation
Délai: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Extended safety assessment at the recommended Phase 2 dose
Délai: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
|
Preliminary efficacy assessment
Délai: Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Repeating sequence of 14 days on therapy and 7 days off or continuous dosing
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 avril 2007
Achèvement primaire (Réel)
1 décembre 2010
Achèvement de l'étude (Réel)
1 décembre 2010
Dates d'inscription aux études
Première soumission
6 mars 2007
Première soumission répondant aux critères de contrôle qualité
6 mars 2007
Première publication (Estimation)
8 mars 2007
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
6 juin 2018
Dernière mise à jour soumise répondant aux critères de contrôle qualité
1 juin 2018
Dernière vérification
1 janvier 2013
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- M06-822
- 2006-003298-28 (Numéro EudraCT)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .